首页> 外文期刊>International immunopharmacology >Blockade of p38 map kinase inhibits complement-induced acute lung injury in a murine model.
【24h】

Blockade of p38 map kinase inhibits complement-induced acute lung injury in a murine model.

机译:在小鼠模型中,p38图激酶的阻断可抑制补体诱导的急性肺损伤。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Features of acute lung injury include neutrophil influx and increased vascular permeability with resultant pulmonary edema. Inhibition of p38 mitogen-activated protein kinase (MAPK) in in vivo models of endotoxin-induced inflammation results in reduction of organ injury as well as symptomatic relief. In this study, mice received an oral dose (100 mg/kg) of the p38 MAPK inhibitor, SB203580, followed by intratracheal instillation of an agent of complement origin, C5a des arg, at a concentration (10 microg) that induced acute lung injury. Neutrophil and protein content of bronchoalveolar lavage fluid as indicators of leukocyte influx and vascular permeability respectively were assessed. Animals that received C5a-instillation had a significant influx of neutrophils into the lungs (49+/-8%) while mice receiving C5a-instillation and prior treatment with SB203580 exhibited diminished influx (16+/-5%). Similarly, pretreatment with oral SB203580 resulted in decreased vascular permeability (241+/-34 microg/ml) than the positive control animals (407+/-135 microg/ml). Activity analysis of total lung p38 MAPK revealed that p38 activity was increased at 4 h after C5a-instillation and that SB203580-treated C5a-instilled mouse lungs had lower p38 activity than did the C5a-instilled control. These data indicate that oral administration of an agent inhibitory for p38 MAPK offers a protective effect in the lungs from both neutrophil influx and protein leak associated with acute lung injury.
机译:急性肺损伤的特征包括嗜中性粒细胞流入和增加的血管通透性并导致肺水肿。在体内毒素诱导的炎症模型中抑制p38丝裂原激活的蛋白激酶(MAPK)可减少器官损伤并减轻症状。在这项研究中,小鼠接受口服剂量(100 mg / kg)的p38 MAPK抑制剂SB203580,然后气管内滴注补体来源的药物C5a des arg,其浓度为(10 microg)会引起急性肺损伤。 。评估支气管肺泡灌洗液中性粒细胞和蛋白质含量分别作为白细胞流入和血管通透性的指标。接受C5a滴注的动物有大量中性粒细胞流入肺(49 +/- 8%),而接受C5a滴注并用SB203580预先治疗的小鼠的流入量减少(16 +/- 5%)。类似地,口服SB203580的预处理与阳性对照动物(407 +/- 135 microg / ml)相比,血管通透性降低(241 +/- 34 microg / ml)。对总肺p38 MAPK的活性分析显示,在C5a滴注后4 h,p38活性增加,并且经SB203580处理的C5a滴注的小鼠肺部的p38活性低于C5a滴注的对照。这些数据表明,口服给予p38 MAPK抑制剂的药物在肺中具有中性粒细胞流入和与急性肺损伤相关的蛋白渗漏的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号